We are live on ! Find out more
MREO

Mereo BioPharma
MREO

63 hedge funds and large institutions have $212M invested in Mereo BioPharma in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 19 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.7% more ownership

Funds ownership: 13.55% → 16.24% (+2.7%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

11% less funds holding

Funds holding: 71 → 63 (-8)

16% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 19

25% less capital invested

Capital invested by funds: $283M → $212M (-$71M)

40% less call options, than puts

Call options by funds: $237K | Put options by funds: $392K

47% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 17

Holders
63
Holders Change
-8
Holders Change %
-11.27%
% of All Funds
1.1%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
9
Increased
16
Reduced
19
Closed
17
Calls
$237K
Puts
$392K
Net Calls
-$155K
Net Calls Change
-$255K

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$45.7M
2
RCMNY
Rubric Capital Management (New York)
New York
+$14.9M
3
VC
Vivo Capital
California
+$7.11M
4
Citadel Advisors
Citadel Advisors
Florida
+$2.97M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.65M

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$19.7M
2
BBA
Baker Bros. Advisors
New York
-$5.74M
3
PA
Perceptive Advisors
New York
-$5.38M
4
ACM
Asymmetry Capital Management
California
-$5.13M
5
TLP
Tri Locum Partners
New York
-$3.97M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$41.8M +$45.7M +17,264,764 New
RCMNY
2
Rubric Capital Management (New York)
New York
$27.3M +$14.9M +5,639,392 +100%
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$24.1M -$350K -132,189 -1%
SCM
4
Suvretta Capital Management
New York
$22.1M +$1.3M +492,767 +6%
VC
5
Vivo Capital
California
$16.7M +$7.11M +2,686,251 +64%
RSCM
6
Rock Springs Capital Management
Maryland
$11.7M +$768K +290,209 +6%
Citadel Advisors
7
Citadel Advisors
Florida
$9.86M +$2.97M +1,120,552 +38%
HA
8
HHLR Advisors
Cayman Islands
$7.2M – – –
Holocene Advisors
9
Holocene Advisors
New York
$5.17M +$496K +187,482 +10%
CC
10
Commodore Capital
New York
$4.78M -$230K -86,771 -4%
Alkeon Capital Management
11
Alkeon Capital Management
New York
$4.68M – – –
TCM
12
Tekla Capital Management
Massachusetts
$3.75M +$1.34M +506,292 +48%
AG
13
Artal Group
Luxembourg
$3.63M – – –
Millennium Management
14
Millennium Management
New York
$3.47M -$607K -229,406 -14%
ACM
15
Altium Capital Management
New York
$3.02M – – –
DCM
16
DAFNA Capital Management
California
$2.73M – – –
Adage Capital Partners
17
Adage Capital Partners
Massachusetts
$2.42M +$2.65M +1,000,000 New
EP
18
Eversept Partners
New York
$2.18M +$2.38M +899,569 New
SSA
19
Schonfeld Strategic Advisors
New York
$1.99M -$1.34M -504,260 -38%
MIM
20
Monashee Investment Management
Massachusetts
$1.94M – – –
ECM
21
Endurant Capital Management
California
$1.81M -$27.5K -10,401 -1%
AAA
22
Affinity Asset Advisors
New York
$1.57M – – –
State Street
23
State Street
Massachusetts
$1M +$886K +334,568 +428%
Renaissance Technologies
24
Renaissance Technologies
New York
$965K +$301K +113,800 +40%
SCM
25
Silverarc Capital Management
Massachusetts
$885K -$106K -40,210 -10%
1
2 3 4

MREO Hedge Fund Activity: Q3 2021 in Review

63 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q3 2021, worth a combined $212M — down 25% from $283M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of MREO and 9 opened new positions — a net loss of 8 holders — while 19 trimmed existing stakes and 16 added.

The largest buyer was OrbiMed, opening a new position worth an estimated $45.7M. The largest seller was Boxer Capital, exiting entirely with an estimated $19.7M sold.

  • 63 institutional investors held Mereo BioPharma (MREO) as of Q3 2021, down from 71 in Q2 2021.
  • Funds reported $212M of Mereo BioPharma stock for Q3 2021, down 25% quarter-over-quarter.
  • 9 funds opened new Mereo BioPharma positions in Q3 2021 and 17 closed out, a net change of -8 holders.
  • The largest Mereo BioPharma buyer in Q3 2021 was OrbiMed, an estimated $45.7M added.
  • The largest Mereo BioPharma seller in Q3 2021 was Boxer Capital, an estimated $19.7M sold.

Based on aggregated 13F filings for Q3 2021.